List of Excipients in Branded Drug LEDIPASVIR AND SOFOSBUVIR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Asegua Therapeutics LLC	LEDIPASVIR AND SOFOSBUVIR	ledipasvir and sofosbuvir	72626-2601	ALCOHOL	2030-11-12
Asegua Therapeutics LLC	LEDIPASVIR AND SOFOSBUVIR	ledipasvir and sofosbuvir	72626-2601	CELLULOSE, MICROCRYSTALLINE	2030-11-12
Asegua Therapeutics LLC	LEDIPASVIR AND SOFOSBUVIR	ledipasvir and sofosbuvir	72626-2601	COPOVIDONE K25-31	2030-11-12
Asegua Therapeutics LLC	LEDIPASVIR AND SOFOSBUVIR	ledipasvir and sofosbuvir	72626-2601	CROSCARMELLOSE SODIUM	2030-11-12
Asegua Therapeutics LLC	LEDIPASVIR AND SOFOSBUVIR	ledipasvir and sofosbuvir	72626-2601	FD&C YELLOW NO. 6	2030-11-12
Asegua Therapeutics LLC	LEDIPASVIR AND SOFOSBUVIR	ledipasvir and sofosbuvir	72626-2601	LACTOSE MONOHYDRATE	2030-11-12
Asegua Therapeutics LLC	LEDIPASVIR AND SOFOSBUVIR	ledipasvir and sofosbuvir	72626-2601	MAGNESIUM STEARATE	2030-11-12

Excipient Strategy and Commercial Opportunities for Ledipasvir and Sofosbuvir

Last updated: September 1, 2026

Ledipasvir/sofosbuvir, marketed by Gilead Sciences as Harvoni, is a fixed-dose oral combination containing 90 mg of ledipasvir and 400 mg of sofosbuvir. Its commercial excipient opportunity is concentrated in generic tablets, formulation development, functional excipient supply, pediatric and regional presentations, and manufacturing processes that reproduce rapid dissolution without infringing formulation claims. The core product uses conventional pharmaceutical excipients, but its performance depends on controlling poorly water-soluble ledipasvir, tablet uniformity, moisture, coating stability, and dissolution across the two active ingredients.[1]

What is the formulation of ledipasvir and sofosbuvir?

Harvoni is an immediate-release, film-coated tablet. The marketed adult strength contains 90 mg of ledipasvir and 400 mg of sofosbuvir.[1]

Which excipients are used in Harvoni tablets?

The FDA prescribing information identifies the following inactive ingredients:[1]

Formulation component	Excipient
Tablet core	Lactose monohydrate
Tablet core	Microcrystalline cellulose
Tablet core	Copovidone
Tablet core	Croscarmellose sodium
Tablet core	Colloidal silicon dioxide
Tablet core	Magnesium stearate
Film coating	Polyvinyl alcohol
Film coating	Titanium dioxide
Film coating	Polyethylene glycol, also identified as macrogol 3350
Film coating	Talc
Film coating	Red iron oxide

This composition indicates a conventional high-dose immediate-release platform. Sofosbuvir accounts for most of the tablet mass, while the excipient system supports the dispersion and release of the lower-dose, poorly soluble ledipasvir component.

Why does ledipasvir require formulation engineering?

Ledipasvir has very low aqueous solubility and is sensitive to pH-dependent dissolution conditions. The commercial formulation must maintain adequate release in the gastrointestinal tract despite changes in gastric and intestinal pH. Copovidone, wetting and disintegration control, particle-size management, and close process control are therefore important formulation variables.[1,2]

Sofosbuvir is also a chemically complex small molecule, but the formulation burden is different. Its 400 mg dose creates a substantial tablet-mass requirement. The excipient system must support content uniformity, mechanical strength, rapid disintegration, and acceptable tablet size.

How does the Harvoni excipient strategy work?

The formulation strategy combines a high-dose active with a low-dose, poorly soluble active in a single immediate-release tablet.

Copovidone

Copovidone is the primary polymeric excipient of commercial interest. It can function as a binder and wetting-support excipient and may help distribute ledipasvir during granulation or blending. In generic development, copovidone grade, molecular-weight distribution, residual moisture, and addition point can affect granule strength and dissolution.

The key commercial opportunity is not simply replacing copovidone. It is supplying a functionally equivalent polymer system that matches:

• ledipasvir dispersion;
• tablet hardness;
• disintegration time;
• dissolution at multiple pH values;
• impurity and stability performance;
• scale-up behavior.

Microcrystalline cellulose and lactose

Microcrystalline cellulose provides compressibility and tablet structure. Lactose monohydrate contributes bulk and improves manufacturability in direct-compression or dry-granulation systems.

For generic manufacturers, the ratio between these two excipients is a practical design variable. Higher microcrystalline cellulose can improve compactability but may alter disintegration and lubrication sensitivity. Lactose grade, particle-size distribution, and hydrate state can affect flow and blend uniformity.

Croscarmellose sodium

Croscarmellose sodium is the principal superdisintegrant identified in the label. Its commercial value is linked to rapid tablet breakup and consistent release of both actives. Excessive levels can increase swelling or affect tablet robustness; insufficient levels can delay dissolution, particularly for the ledipasvir fraction.

Colloidal silicon dioxide

Colloidal silicon dioxide supports powder flow and may improve handling of low-dose ledipasvir during blending. It also can influence lubricant distribution and tablet tensile strength. The supplier opportunity lies in consistent surface area, moisture control, and grade selection rather than in simple volume substitution.

Magnesium stearate

Magnesium stearate reduces ejection force and limits sticking during compression. Over-lubrication can slow wetting and dissolution. Generic developers must control blending time, lubricant concentration, and shear because dissolution performance may be affected even when assay and hardness remain within specification.

Film coating

The film coat contains polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and red iron oxide.[1] The coating provides color, surface protection, swallowability, and brand identification. It also creates opportunities for alternative coating systems using equivalent pigments, plasticizers, and polymer grades, subject to regulatory requirements and product appearance controls.

What excipient characteristics matter most for generic ledipasvir/sofosbuvir?

The highest-value attributes are functional performance and lot-to-lot consistency.

Critical quality attribute	Relevant excipient drivers
Dissolution	Disintegrant activity, polymer wetting, lubricant level, API particle size
Content uniformity	Ledipasvir particle distribution, carrier flow, blending sequence
Tablet hardness	Microcrystalline cellulose, lactose grade, compression force
Disintegration	Croscarmellose sodium, tablet porosity, lubricant overuse
Stability	Moisture, peroxide burden, excipient impurities, packaging
Manufacturability	Flow, bulk density, ejection force, sticking tendency
Appearance	Coating polymer, pigment dispersion, plasticizer balance

Excipient suppliers with documented pharmaceutical-grade manufacturing, extractables and leachables data, elemental impurity controls, residual-solvent data, and global regulatory packages have a competitive advantage.

What formulation alternatives could compete with the Harvoni tablet?

The principal development paths are conventional tablets, modified immediate-release tablets, dispersible tablets, oral granules, and pediatric liquid-oriented presentations.

Conventional immediate-release tablets

This is the most commercially practical route for adult generic products. The objective is bioequivalence and comparable dissolution using a formulation that may differ in qualitative or quantitative excipient composition.

A generic developer can pursue:

• wet granulation;
• dry granulation;
• direct compression;
• separate granulation of ledipasvir and sofosbuvir;
• API co-processing with a polymeric carrier;
• coated or uncoated multiparticulate intermediates compressed into tablets.

The lowest-risk route generally preserves the reference product’s immediate-release behavior while avoiding unnecessary excipient novelty.

Amorphous solid dispersion approaches

An amorphous solid dispersion could improve ledipasvir apparent solubility, but it creates added development burdens. These include physical stability, recrystallization risk, polymer selection, residual solvent control, and process validation.

Potential polymers include copovidone, povidone, hypromellose, and hypromellose acetate succinate. The commercial advantage would be a smaller tablet, improved dissolution margin, or improved robustness under variable gastrointestinal conditions. The disadvantages are higher process complexity and possible patent exposure around dispersion methods or compositions.

Pediatric and dispersible formats

Harvoni received FDA approval for pediatric patients, including younger children, through expanded dosage forms and strengths.[3] Pediatric opportunities include oral pellets, granules, dispersible tablets, and taste-masked powders. These products require control of:

• dose flexibility;
• swallowability;
• taste masking;
• redispersion;
• sedimentation;
• dose uniformity;
• caregiver handling;
• compatibility with food and liquids.

Taste-masking systems based on ion-exchange resins, lipid barriers, polymer coatings, or sweetener combinations may create differentiated products. Any pediatric product must also address dosing accuracy and age-appropriate administration.

What regulatory pathway applies to generic ledipasvir and sofosbuvir?

Ledipasvir/sofosbuvir is a small-molecule combination product. A US generic would generally proceed through an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act, with pharmaceutical equivalence, bioequivalence, quality, and labeling requirements.[4]

The generic must demonstrate that the product has the same active ingredients, dosage form, strength, route of administration, and conditions of use as the reference listed drug, subject to permitted differences. Excipients may differ if the product meets applicable regulatory standards and does not affect safety, efficacy, or bioequivalence.

For poorly soluble compounds, comparative dissolution is commercially important. A formulation may pass basic quality testing while creating regulatory risk if its dissolution profile diverges from the reference product under discriminatory conditions.

What FDA status does Harvoni have?

Harvoni was approved by FDA in October 2014 for chronic hepatitis C virus infection. Its active ingredients are ledipasvir and sofosbuvir, both direct-acting antiviral agents.[1] The combination is a small molecule, not a biologic, so biosimilar approval under the Public Health Service Act is not the relevant pathway.

The product’s original regulatory exclusivity has expired. Commercial entry is therefore governed primarily by patent certifications, settlements, manufacturing readiness, market access, and regional demand.

What is the Orange Book and patent position for ledipasvir/sofosbuvir?

FDA’s Orange Book identifies patents and regulatory exclusivity associated with approved drug products. Harvoni’s relevant patent records should be assessed by product, active ingredient, formulation, and method of use rather than by assuming that all patents cover the same commercial risk.[5]

Which patent categories matter?

The principal categories are:

1. Ledipasvir composition and use patents.
2. Sofosbuvir composition and use patents.
3. Combination-treatment patents.
4. Pharmaceutical composition and formulation patents.
5. Solid-state, process, and manufacturing patents.
6. Method-of-use patents covering hepatitis C genotypes, treatment durations, or patient populations.

A generic applicant must evaluate Paragraph I, II, III, and IV certification positions for each listed patent. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed. Filing can create litigation exposure and may trigger a 30-month stay if the patent owner brings a timely infringement action.[4,5]

When does ledipasvir/sofosbuvir lose exclusivity?

The original FDA exclusivity periods have expired, but patent protection may extend beyond regulatory exclusivity. The relevant entry date depends on the Orange Book patent list, patent-term adjustments, pediatric exclusivity, litigation outcomes, and settlement provisions.

The commercial analysis should separate:

Exclusivity type	Relevance
New chemical entity exclusivity	Expired for the original active ingredients
Three-year clinical-investigation exclusivity	Expired for the original combination approval
Pediatric exclusivity	May extend listed patent or exclusivity periods when granted
Orange Book patents	Can delay or restrict generic approval or launch
Non-Orange Book patents	May create litigation or manufacturing risk without automatically blocking ANDA approval
Settlement agreements	May establish an agreed generic entry date or license conditions

Patent expiration is not the same as market entry. A generic may launch through an authorized arrangement, a settlement license, an independent Paragraph IV strategy, or an at-risk launch.

Which companies are challenging or competing with Harvoni?

Competition has shifted from branded direct-acting antivirals to lower-cost generic and regional products. Major competing regimens have included:

Product	Active ingredients	Sponsor or major marketer	Commercial relevance
Harvoni	Ledipasvir/sofosbuvir	Gilead Sciences	Reference product
Epclusa	Sofosbuvir/velpatasvir	Gilead Sciences	Broader genotype coverage
Mavyret	Glecaprevir/pibrentasvir	AbbVie	Short-course, competitive pricing
Sovaldi	Sofosbuvir	Gilead Sciences	Single-agent predecessor
Generic ledipasvir/sofosbuvir	Ledipasvir/sofosbuvir	Regional and generic manufacturers	Price-led competition

The principal competitive risk is substitution by pan-genotypic regimens, particularly sofosbuvir/velpatasvir and glecaprevir/pibrentasvir. Harvoni remains relevant where genotype-specific clinical practice, procurement history, local guidelines, or price support continued use.

What commercial opportunities exist for excipient suppliers?

The largest opportunities are in differentiated functional excipients and supply-chain services rather than in commodity lactose or magnesium stearate.

High-value opportunity areas

Functional copovidone systems

Suppliers can offer copovidone grades optimized for wetting, binding, low peroxide content, and reproducible dissolution. Technical packages that support formulation bridging and regulatory submissions can increase switching costs.

Co-processed filler-disintegrant systems

Co-processed lactose, microcrystalline cellulose, and superdisintegrant systems can simplify manufacturing and improve blend uniformity. These products are most attractive for manufacturers pursuing direct compression.

Low-moisture and low-peroxide excipients

Chemical stability programs may favor excipients with controlled moisture and oxidative impurity profiles. Such grades can reduce development variability and improve shelf-life margins.

Ready-to-use film-coating systems

Color-matched, aqueous film-coating systems can reduce development time and improve batch consistency. Suppliers can compete through regulatory documentation, pigment control, and global manufacturing capacity.

Pediatric taste-masking platforms

Taste-masked powders, pellets, and dispersible formats provide a more defensible commercial niche than standard adult tablets. The strongest offerings combine taste masking with dose flexibility and low-volume administration.

Contract development and manufacturing

Contract manufacturers can offer segregated handling of low-dose ledipasvir, analytical method transfer, dissolution development, scale-up, and stability programs. These services are valuable to regional generic companies lacking internal formulation infrastructure.

How strong is the formulation IP position?

The formulation IP position is potentially narrower than the active-ingredient estate but can still affect design freedom. Risk areas include a specific excipient combination, particle-size distribution, solid dispersion, dosage form, dissolution profile, manufacturing sequence, or pediatric presentation.

A practical freedom-to-operate review should map:

• each formulation claim to the actual excipient composition;
• claim scope against the proposed generic formulation;
• process claims against the intended manufacturing route;
• geographic coverage;
• patent term and terminal disclaimers;
• settlement restrictions;
• non-Orange Book patents;
• supplier-specific know-how and confidentiality obligations.

A formulation that uses the same excipient names as Harvoni is not automatically infringing. Conversely, changing one excipient does not necessarily avoid a claim if the claim covers a broader composition or process.

What generic launch scenarios exist?

Authorized or licensed launch

A licensed launch can provide earlier entry and lower litigation risk but may involve royalties, supply restrictions, geographic limitations, or volume commitments.

Paragraph IV launch

A Paragraph IV strategy can provide substantial upside if the relevant patents are defeated or entry is otherwise permitted. It carries litigation costs, possible damages exposure, and launch uncertainty.

Post-patent conventional launch

A manufacturer can wait for relevant patent barriers to expire and enter with a standard immediate-release tablet. This reduces legal risk but may sacrifice first-mover economics.

Regional launch

Markets with public-health procurement, voluntary licensing, or different patent rules can support earlier generic sales. The largest opportunities are in hepatitis C treatment programs where procurement price, genotype coverage, and simplified treatment pathways drive purchasing decisions.

What revenue exposure does Harvoni create?

Harvoni was one of Gilead’s largest commercial products, generating approximately $13.9 billion in worldwide product sales in 2015 before declining as the treated population decreased and competing regimens expanded.[6] The commercial exposure has since shifted from brand revenue to residual demand, price erosion, licensing economics, and portfolio substitution.

For generic manufacturers, revenue depends on:

• remaining diagnosed patients;
• genotype-specific prescribing;
• government and tender purchasing;
• treatment duration;
• competition from pan-genotypic therapies;
• manufacturing cost per tablet;
• market-specific patent status;
• ability to secure bioequivalence and regulatory approval.

The product remains commercially viable where manufacturing costs are low and procurement channels reward established ledipasvir/sofosbuvir supply.

Key Takeaways

• Harvoni uses a conventional immediate-release tablet with lactose, microcrystalline cellulose, copovidone, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and a polyvinyl alcohol film coat.[1]
• Ledipasvir creates the principal solubility and dissolution challenge.
• Sofosbuvir creates tablet-mass, compression, and content-uniformity requirements.
• Generic developers can pursue wet granulation, dry granulation, direct compression, or dispersion-based approaches.
• Functional copovidone, low-moisture excipients, co-processed fillers, film-coating systems, and pediatric taste-masking platforms offer the strongest supplier opportunities.
• FDA exclusivity has expired, but Orange Book patents, Paragraph IV certifications, litigation, and settlements remain relevant to launch timing.
• Harvoni has no biosimilar pathway because it is a small-molecule drug.
• Pan-genotypic competitors, especially sofosbuvir/velpatasvir and glecaprevir/pibrentasvir, constrain long-term branded and generic pricing.
• Pediatric dispersible, granule, and taste-masked presentations offer more defensible differentiation than a standard adult tablet.

FAQs

Can ledipasvir and sofosbuvir be formulated as a liquid?

A liquid or reconstitutable product is technically possible, but chemical stability, solubility, taste masking, dose uniformity, and packaging impose substantial development requirements. Granules or dispersible tablets may offer a more practical pediatric platform.

Which excipient is most important for ledipasvir dissolution?

Copovidone is a key formulation excipient, but dissolution depends on the full system, including ledipasvir particle size, disintegrant activity, lubricant level, tablet porosity, and process conditions.

Is a generic Harvoni tablet required to use the same excipients?

No. A generic may use different excipients if it meets FDA requirements for quality, safety, pharmaceutical equivalence, bioequivalence, and product performance.[4]

Are excipient patents a major barrier to generic ledipasvir/sofosbuvir?

They can be. The relevant risk depends on the scope and enforceability of formulation, solid-state, process, and pediatric dosage-form claims. Excipient substitution alone does not establish freedom to operate.

Which formulation has the best commercial potential?

For adult treatment, a conventional immediate-release tablet has the clearest regulatory and manufacturing path. For differentiated growth, pediatric granules, dispersible tablets, and taste-masked multiparticulates offer greater commercial separation.

References

1. U.S. Food and Drug Administration. (2024). Harvoni prescribing information. Gilead Sciences, Inc. https://www.accessdata.fda.gov
2. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. https://www.ich.org
3. U.S. Food and Drug Administration. (2017). FDA approves expanded use of Harvoni for pediatric patients with chronic hepatitis C. https://www.fda.gov
4. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov
6. Gilead Sciences, Inc. (2016). Annual report for the fiscal year ended December 31, 2015. https://investors.gilead.com